To enhance generative artificial intelligence (GenAI), Amazon Web Services (AWS) and Nvidia are prolonging their 13-year partnership.
The firms stated in a press release on Monday, March 18, that this partnership intends to introduce the new Nvidia Blackwell GPU platform to AWS, providing clients with cutting-edge and safe infrastructure, software, and services.
According to the release, the GB200 Grace Blackwell Superchip and B100 Tensor Core GPUs are part of the Nvidia Blackwell platform. This platform allows customers to build and run multitrillion parameter large language models (LLMs) faster, at a massive scale, and securely. It does this by combining AWS’s Elastic Fabric Adapter Networking with the hyper-scale clustering of Amazon EC2 UltraClusters and the advanced virtualization and security features of the Nitro system.
According to the release, AWS intends to provide EC2 instances with the new B100 GPUs installed in EC2 UltraClusters to accelerate large-scale generative AI training and inference.
Nvidia founder and CEO Jensen Huang stated in the press release that “our partnership with AWS is accelerating new generative AI capabilities and providing customers with unprecedented computing power to push the boundaries of what’s possible.”
“We currently offer the widest range of Nvidia GPU solutions for customers,” said Adam Selipsky, CEO of AWS, “and the deep collaboration between our two organizations goes back more than 13 years, when together we launched the world’s first GPU cloud instance on AWS.”
This partnership places a high priority on security, the release states. To prevent unauthorized access to model weights and encrypt data transfer, the AWS Nitro System, AWS Key Management Service (AWS KMS), encrypted Elastic Fabric Adapter (EFA), and Blackwell encryption are integrated.
According to the release, the cooperation goes beyond hardware and infrastructure. Additionally, AWS and Nvidia are collaborating to hasten the creation of GenAI applications across a range of sectors. They provide generative AI inference through the integration of Nvidia NIM inference microservices with Amazon SageMaker.
In the healthcare and life sciences sector, AWS and Nvidia are expanding computer-aided drug discovery with new Nvidia BioNeMo FMs for generative chemistry, protein structure prediction, and understanding how drug molecules interact with targets, per the release. These models will be available on AWS HealthOmics, a service purpose-built for healthcare and life sciences organizations.
The partnership’s extension occurs at a time when interest in artificial intelligence has caused Nvidia’s valuation to soar in just nine months, from $1 trillion to over $2 trillion. With an 80% market share, the company dominates the high-end AI chip market.
AWS has been releasing GenAI-powered tools for various industries concurrently.